Amycretin vs CagriSema: Which GLP-1/Amylin Therapy Wins in 2026?

The race to develop the most effective obesity pharmacotherapy has taken a fascinating turn: Novo Nordisk is now running two distinct GLP-1/amylin combination strategies against each other — or rather, in parallel. Amycretin is a single unimolecular dual agonist that hits GLP-1 and amylin receptors simultaneously. CagriSema co-administers two separate, independently validated molecules — semaglutide and cagrilintide — in a fixed-ratio weekly injection.

If you're following next-generation obesity research — or trying to understand where GLP-1 science is heading — this comparison breaks down the mechanism, clinical data, safety profiles, and development status of both approaches so you can make sense of what the evidence actually shows.

How Each Therapy Works: Unimolecular vs. Combination

Understanding the mechanistic difference between amycretin and CagriSema is the foundation of this comparison. Both exploit the same biological pathways — GLP-1 receptor agonism and amylin receptor agonism — but the molecular architecture is entirely different.

Amycretin: One Molecule, Two Receptors

Amycretin is a novel unimolecular dual agonist designed to activate both the GLP-1 receptor (GLP-1R) and the amylin receptor (AMY receptor complex) from a single peptide chain. This represents one of the most elegant approaches to multi-pathway obesity pharmacology: rather than co-formulating two drugs, Novo Nordisk's chemists engineered a single molecule capable of simultaneous dual engagement.

GLP-1 receptor agonism reduces appetite and slows gastric emptying. Amylin receptor agonism contributes to satiety signaling through the central nervous system, particularly the hypothalamus and brainstem. The combination is theoretically synergistic — both pathways reduce caloric intake through distinct but complementary mechanisms. Amycretin is also notable for being available in both subcutaneous and oral formulations, making it potentially the first oral dual GLP-1/amylin agonist.

CagriSema: Two Proven Molecules, One Injection

CagriSema combines semaglutide 2.4 mg (the GLP-1 agonist in Wegovy) with cagrilintide 2.4 mg (a long-acting amylin analog) in a single weekly subcutaneous injection. Each component has an independent phase 3 evidence base. Semaglutide's efficacy and safety are exceptionally well characterized. Cagrilintide has its own clinical program validating its standalone activity. The combination approach allows each molecule to be optimized independently before pairing.

Weight Loss Data: What the Trials Actually Show

This is where the comparison gets substantive. Both therapies have produced compelling weight loss numbers, but at different stages of development with different levels of evidence certainty.

Amycretin Clinical Data (Phase 1/2)

Amycretin's pivotal early data was published in The Lancet in 2025 from a phase 1b/2a randomized controlled study. In adults with overweight or obesity, subcutaneous amycretin produced up to 24% weight loss at 36 weeks — a figure that significantly exceeded expectations and drew immediate attention from the obesity research community.

A separate phase 2 study in people with type 2 diabetes (T2D) showed up to 14.5% weight loss at 36 weeks with subcutaneous dosing. The oral formulation, assessed in a phase 1 study, produced 13.1% weight reduction at just 12 weeks — a remarkable result for an oral peptide, a class historically plagued by poor bioavailability. Phase 3 initiation in overweight/obese adults is planned for Q1 2026.

CagriSema Clinical Data (Phase 3 Completed)

CagriSema's phase 3 REDEFINE program, published in the New England Journal of Medicine in 2025, enrolled over 4,600 participants across two pivotal trials.

• REDEFINE 1 (adults with obesity/overweight, without T2D): Mean weight loss of 20.4% at 68 weeks vs 3.0% placebo. Approximately 60% of participants achieved ≥20% weight loss; 23% achieved ≥30%.
• REDEFINE 2 (adults with T2D): Mean weight loss of 13.7% at 68 weeks.

These are phase 3 results — the gold standard of clinical evidence — making CagriSema's data considerably more mature and reliable than amycretin's at this stage. The 68-week trial duration also provides a more complete picture of long-term efficacy and safety than 36-week phase 2 data can offer.

Side Effects and Tolerability: How Do They Compare?

Both therapies share a side effect profile consistent with GLP-1 and amylin receptor agonism — predominantly gastrointestinal — but the quantification differs significantly given the difference in trial size and stage.

Amycretin Safety

In phase 1b/2a trials, amycretin's adverse events were predominantly GI in nature: nausea, vomiting, and decreased appetite were most commonly reported. The safety profile appeared consistent with what would be expected from dual GLP-1/amylin engagement. Both the subcutaneous and oral formulations were described as generally well tolerated, with most events rated mild to moderate in severity. No unexpected safety signals were reported in early-phase data, though the participant numbers are far smaller than CagriSema's phase 3 program.

CagriSema Safety

REDEFINE 1 provided the most comprehensive safety picture: GI adverse events affected 79.6% of CagriSema-treated participants vs 39.9% in the placebo group. Events included nausea, vomiting, diarrhea, constipation, and abdominal pain. The majority were mild to moderate and transient — most intensive during dose titration. Serious adverse events occurred at rates broadly comparable to other GLP-1 class agents.

Importantly, CagriSema's safety profile is reinforced by the independent clinical histories of its components. Semaglutide's long-term safety data spans years and tens of thousands of patients. Cagrilintide's standalone tolerability has also been independently evaluated. This dual validation is a meaningful advantage for CagriSema in terms of safety confidence.

Amycretin vs CagriSema: Side-by-Side

Why Novo Nordisk Is Running Both Programs

A natural question arises: why would Novo Nordisk develop two therapies that target the same receptor pathways? The answer is strategic, scientific, and commercial.

Novo Nordisk has publicly stated that its base case is amycretin replacing CagriSema as the lead dual GLP-1/amylin asset — the unimolecular approach is conceptually cleaner, manufacturing potentially simpler, and the oral formulation option is a major differentiator in an increasingly competitive obesity market. However, CagriSema's completed phase 3 data means it can reach regulatory submission sooner, providing a near-term commercial asset while amycretin completes its longer development journey.

The parallel development also hedges risk: if amycretin encounters unexpected safety issues at phase 3 scale, CagriSema provides continuity. Conversely, if amycretin's phase 3 results confirm the extraordinary early signals, it could obsolete CagriSema before the latter even reaches market in some geographies.

For researchers and clinicians tracking this space, this means both molecules are scientifically relevant and worth monitoring — they represent different engineering philosophies applied to the same biological problem, and the comparative outcomes will inform how the entire field approaches multi-receptor obesity pharmacology.

Frequently Asked Questions

The Verdict: Where Does Each Therapy Stand?

CagriSema is the more evidence-mature option today — with completed phase 3 trials, large participant populations, and NEJM-published results providing a high level of confidence in its 20.4% weight loss efficacy and safety characterization. For anyone tracking obesity pharmacology developments that are closest to clinical availability, CagriSema is the nearer-term story.

Amycretin is the more scientifically exciting option — the unimolecular design is novel, the oral formulation is potentially transformative, and its early weight loss numbers have set expectations very high for phase 3. If amycretin replicates its phase 1b/2a results in a large-scale trial, it could represent a meaningful step forward even beyond CagriSema's already impressive benchmarks.

For researchers following the GLP-1 and amylin space alongside other investigational peptides like retatrutide (a GIP/GLP-1/glucagon triple agonist) and ipamorelin, the amycretin vs CagriSema comparison illustrates a broader principle: the field is rapidly moving from single-receptor to multi-receptor strategies, and the optimal molecular architecture for achieving that remains an open scientific question.

Watch the phase 3 amycretin readout — expected 2027-2028 — as the definitive data point that will settle much of this debate.